CAR-T Neurotoxicity (ICANS) Assessment Service for Blood-Brain Barrier (BBB) Chip Model

CAR-T cell therapy faces significant challenges from unpredictable neurotoxicity, a limited understanding of its underlying mechanisms in humans, and a critical lack of physiologically relevant preclinical models to accurately assess blood-brain barrier (BBB) disruption. Creative Biolabs' CAR-T Neurotoxicity (ICANS) Assessment Service directly addresses this gap. We employ a proprietary 3D BBB-on-a-chip platform that faithfully recapitulates the human neurovascular unit under dynamic flow conditions. This service provides you with robust, human-relevant data on endothelial activation, cytokine-mediated neuroinflammation, and CAR-T cell extravasation, enabling predictive safety profiling to de-risk your candidates and strengthen your regulatory submissions.

Introduction

While CAR-T cell therapy represents a transformative advance in treating relapsed or refractory hematologic malignancies, the risk of immune effector cell-associated neurotoxicity syndrome (ICANS) continues to pose a significant clinical challenge. Patients with central nervous system (CNS) involvement have traditionally been excluded from pivotal trials due to concerns over potentially heightened neurotoxicity. Emerging evidence, however, indicates that a history of CNS disease does not markedly elevate the incidence or severity of ICANS. Therefore, pre-existing CNS involvement should not be considered an absolute contraindication to CAR-T therapy, although rigorous, neurologist-supervised monitoring remains imperative in this patient population.

Fig.1 Central nervous system neurotoxicity in CAR-T cell therapy for hematologic disorders.¹

CAR-T Neurotoxicity (ICANS) Assessment Service for Blood-Brain Barrier (BBB) Chip Model at Creative Biolabs

Creative Biolabs provides a specialized platform designed to bridge the gap between traditional 2D assays and complex clinical trials. Our service allows developers to quantify the neurotoxic potential of CAR-T and other TCR-based therapies by observing real-time interactions at the human blood-brain interface. By utilizing primary human pericytes, astrocytes, and brain endothelial cells, we deliver predictive data that standard animal models, which often lack human-specific CD19 or BCMA expression in the CNS, simply cannot provide.

What We Can Offer

Our service offers a human-relevant, predictive assessment platform for CAR-T neurotoxicity. We provide a high-fidelity 3D BBB-on-a-chip model that recapitulates key physiological interactions, coupled with a suite of comprehensive multi-parametric analyses to quantify barrier disruption, cellular injury, and neuroinflammatory cascades.

Our Service Process

Required Starting Materials:

• The CAR-T construct sequence.
• Target antigen profiles.
• Any existing in vitro cytotoxicity data.

Key Steps:

Final Deliverables: A formal Preclinical Safety Report including high-resolution microscopy images and a neurotoxicity risk stratification profile.

Key Advantages

• Customized Antigen Profiling: We engineer specialized cell lines to express clinically relevant target antigens, enabling high-resolution assessment of off-target T-cell engagement with human brain pericytes—a critical step in predicting ICANS.
• Advanced Cytokine Profiling: Our platform performs high-throughput, multiplex analysis of key neuroinflammatory markers (e.g., IL-6, Angiopoietin-2) within distinct vascular and neural compartments, providing compartmentalized insight into cytokine release dynamics.
• Customized Interventional Testing: We integrate prophylactic agents directly into the microfluidic circuit to quantitatively evaluate their ability to mitigate endothelial activation, stabilize barrier integrity, and prevent immune-mediated neurovascular damage in a dynamic human model.

FAQs

Why Choose Us?

Creative Biolabs provides a uniquely predictive platform for assessing CAR-T neurotoxicity (ICANS) by integrating human-centric models with advanced microfluidic technology. Our BBB Chip utilizes authentic human CNS cells under dynamic flow, enabling precise detection of pathological T-cell adhesion—the "Pericyte Connection." This approach generates clinically relevant, biomarker-correlated data far superior to animal models, offering a reliable, human-relevant solution for de-risking neurotoxicity in preclinical development.

Customer Reviews

How to Contact Us?

To access our industry-leading BBB Chip model for predictive ICANS safety data and de-risk your CAR-T development, contact our expert team. We provide tailored project consultations and proposals. Contact us or visit our website to schedule a technical discussion.

Reference

1. Velasco, Roser et al. "CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?" Frontiers in neurology vol. 14 1144414. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fneur.2023.1144414.